MIANGUAN2 Alleviates Influenza Virus Infection by Modulating Gut Microbiota and Enhancing Short-Chain Fatty Acid Production

Overview

Journal Nutrients

Date 2024 Jun 27

PMID 38931277

Authors

Yulu Chen

Liqiong Song

Mengshan Chen

Yuanming Huang

Zhihuan Wang

Zhihong Ren

Jianguo Xu

Affiliations

Soon will be listed here.

Abstract

Influenza, a severe respiratory disease caused by the influenza virus, has long been a prominent threat to human health. An increasing number of studies have demonstrated that oral administration with probiotics may increase the immune response to lung infection via the gut-lung axis leading to the alleviation of the pulmonary disease. In this study, we evaluated the effects of oral administration of MIANGUAN2 (MIANGUAN2) on influenza infection in a mouse model. Our results showed that oral administration of MIANGUAN2 significantly improved weight loss, lung index, and lung pathology, and decreased lung viral load of influenza-infected mice. Additionally, MIANGUAN2-treated mice showed significantly lower levels of TNF-α, IL-1β, IFN-γ, and IL-12p70 and higher production of IL-4 in the lung. In accordance with this, the transcriptome analysis of the lung indicated that MIANGUAN2-treated mice had reduced expression of inflammation markers, such as TNF, apoptosis, and the NF-Kappa B pathway. Furthermore, the administration of MIANGUAN2 restored the SCFAs profiles through regulating the gut microbiota. SCFA-producing bacteria, such as p_Firmicutes, f_Lachnospiraceae, and f_Ruminococcaceae, were enriched in the MIANGUAN2-treated group compared with PBS-treated group. Consistently, the concentrations of SCFAs in the MIANGUAN2 group were significantly higher than those in the PBS-treated group. In addition, the concentrations of SCFAs were positively correlated with SCFA-producing bacteria, such as , while being negatively correlated with the virial titers and proinflammatory cytokines. In conclusion, this animal study suggests that MIANGUAN2 may alleviate the influenza infection by altering the gut microbiota composition and increasing the levels of gut microbiota-derived SCFAs.

References

Vital M, Howe A, Tiedje J . Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. mBio. 2014; 5(2):e00889. PMC: 3994512. DOI: 10.1128/mBio.00889-14. View

Ashique S, De Rubis G, Sirohi E, Mishra N, Rihan M, Garg A . Short Chain Fatty Acids: Fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases. Chem Biol Interact. 2022; 368:110231. DOI: 10.1016/j.cbi.2022.110231. View

Rello J, Pop-Vicas A . Clinical review: primary influenza viral pneumonia. Crit Care. 2010; 13(6):235. PMC: 2811908. DOI: 10.1186/cc8183. View

Varfolomeev E, Vucic D . Intracellular regulation of TNF activity in health and disease. Cytokine. 2016; 101:26-32. DOI: 10.1016/j.cyto.2016.08.035. View

Deriu E, Boxx G, He X, Pan C, Benavidez S, Cen L . Influenza Virus Affects Intestinal Microbiota and Secondary Salmonella Infection in the Gut through Type I Interferons. PLoS Pathog. 2016; 12(5):e1005572. PMC: 4858270. DOI: 10.1371/journal.ppat.1005572. View

Kiraz Y, Adan A, Yandim M, Baran Y . Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol. 2016; 37(7):8471-86. DOI: 10.1007/s13277-016-5035-9. View

Mahooti M, Abdolalipour E, Salehzadeh A, Mohebbi S, Gorji A, Ghaemi A . Immunomodulatory and prophylactic effects of Bifidobacterium bifidum probiotic strain on influenza infection in mice. World J Microbiol Biotechnol. 2019; 35(6):91. DOI: 10.1007/s11274-019-2667-0. View

Le B, Kim D, Phuoc N, Linh N, Yang S . Dietary supplementation with Pediococcus pentosaceus enhances the innate immune response in and promotes growth of Litopenaeus vannamei shrimp. J Fish Dis. 2022; 45(9):1343-1354. DOI: 10.1111/jfd.13666. View

Lee I, Kim Y, Park S, Chun J . OrthoANI: An improved algorithm and software for calculating average nucleotide identity. Int J Syst Evol Microbiol. 2015; 66(2):1100-1103. DOI: 10.1099/ijsem.0.000760. View

10.

Rastogi S, Mohanty S, Sharma S, Tripathi P . Possible role of gut microbes and host's immune response in gut-lung homeostasis. Front Immunol. 2022; 13:954339. PMC: 9581402. DOI: 10.3389/fimmu.2022.954339. View

11.

Sencio V, Gallerand A, Machado M, Deruyter L, Heumel S, Soulard D . Influenza Virus Infection Impairs the Gut's Barrier Properties and Favors Secondary Enteric Bacterial Infection through Reduced Production of Short-Chain Fatty Acids. Infect Immun. 2021; 89(9):e0073420. PMC: 8370677. DOI: 10.1128/IAI.00734-20. View

12.

Ghorbani P, Santhakumar P, Hu Q, Djiadeu P, Wolever T, Palaniyar N . Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth. Eur Respir J. 2015; 46(4):1033-45. DOI: 10.1183/09031936.00143614. View

13.

Rooks M, Garrett W . Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016; 16(6):341-52. PMC: 5541232. DOI: 10.1038/nri.2016.42. View

14.

Smyk J, Szydlowska N, Szulc W, Majewska A . Evolution of Influenza Viruses-Drug Resistance, Treatment Options, and Prospects. Int J Mol Sci. 2022; 23(20). PMC: 9602850. DOI: 10.3390/ijms232012244. View

15.

Zhai Q, Feng S, Arjan N, Chen W . A next generation probiotic, . Crit Rev Food Sci Nutr. 2018; 59(19):3227-3236. DOI: 10.1080/10408398.2018.1517725. View

16.

Monto A, Gravenstein S, Elliott M, Colopy M, Schweinle J . Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000; 160(21):3243-7. DOI: 10.1001/archinte.160.21.3243. View

17.

Toapanta F, Ross T . Impaired immune responses in the lungs of aged mice following influenza infection. Respir Res. 2009; 10:112. PMC: 2785782. DOI: 10.1186/1465-9921-10-112. View

18.

Ludwig S, Planz O . Influenza viruses and the NF-kappaB signaling pathway - towards a novel concept of antiviral therapy. Biol Chem. 2008; 389(10):1307-12. DOI: 10.1515/BC.2008.148. View

19.

Bradley K, Finsterbusch K, Schnepf D, Crotta S, Llorian M, Davidson S . Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection. Cell Rep. 2019; 28(1):245-256.e4. DOI: 10.1016/j.celrep.2019.05.105. View

20.

Mahooti M, Miri S, Abdolalipour E, Ghaemi A . The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment?. Microb Pathog. 2020; 148:104452. PMC: 7431320. DOI: 10.1016/j.micpath.2020.104452. View